drugset / Trial / NCT06773507
Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors
Phase 1
Recruiting
80 enrolled
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this study is to learn if BC008-1A given 900mg or 1200mg intravenously once every 3 weeks is safe and effective to treat patients with advanced esophageal cancer or advanced non-small cell lung cancer. It will also learn about the safety and pharmacokinetics of BC008-1A.
Timeline
- Start
- 2025-05-12
- Primary completion
- 2026-06
- Completion
- 2027-06